Why did PME.AX stock fall so sharply today?

The fall followed a re-rate after strong H1 results including large fair-value gains; high trading volume (**1,455,611**) and rich valuation (P/E **117.27**) triggered profit-taking and repositioning by investors.

What is Meyka AI's view on PME.AX stock?

Meyka AI grades PME.AX **79.19/100 (B+, BUY)** and models a monthly target of **A$118.66** and a 1-year projection of **A$355.28**. These are model projections and not guarantees.

What technical levels should traders watch for PME.AX stock?

Watch immediate support near **A$110.00**, resistance at the 50-day average **A$204.50**, RSI (**29.53**) and ATR (**A$7.18**) for volatility cues in the short term.

Does Pro Medicus pay dividends after the H1 result?

Yes. Management declared a fully franked interim dividend of **A$0.32** per share, payable on March 20, reflecting strong cash flow and capital allocation.

AU Stocks

PME.AX Pro Medicus down 29% at ASX close 13 Feb 2026: key levels

ByDanny Kontos February 13, 2026

PME.AX stock plunged 29.49% to A$118.22 at the ASX close on 13 Feb 2026, marking one of the biggest single-day drops for Pro Medicus Limited (ASX). Trading volume surged to 1,455,611 shares, almost 4.60 times average, as the market assessed a strong half-year result alongside large fair-value gains. The sell-off reversed recent momentum: the 50-day average is A$204.50 and the 200-day average is A$268.41, highlighting an abrupt re-rating in the Australian healthcare software leader.